Digital Content 
NEWS #PharmaBuzz
04 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/06/2992829/0/en/New-Phase-IIIB-data-shows-Novartis-Fabhalta-improved-hemoglobin-levels-in-adult-patients-with-paroxysmal-nocturnal-hemoglobinuria-who-switched-from-anti-C5-therapy.html
19 Sep 2024
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108
28 Jun 2024
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108
23 Apr 2024
// PRESS RELEASE
https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-approved-in-the-eu-as-add-on-treatment-to-ravulizumab-or-eculizumab-for-adults-with-rare-disease-pnh-who-have-residual-haemolytic-anaemia.html#:~:text=Voydeya%20(danicopan)%20has%20been%20approved,who%20have%20residual%20haemolytic%20anaemia.
18 Apr 2024
// Andrea Park FIERCE PHARMA
https://www.fiercepharma.com/marketing/astrazenecas-alexion-takes-nmosd-awareness-campaign-long-form-new-film-highlighting
08 Apr 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/04/08/2859605/0/en/Onco360-Has-Been-Selected-as-the-Sole-National-Specialty-Pharmacy-Partner-for-Voydeya-danicopan.html
Share 